A large-scale study reveals azvudine’s comparable efficacy to Paxlovid, fewer adverse effects, and potential antitumor benefits in patients with liver cancer.
Study: Real‐world effectiveness and safety of oral azvudine versus nirmatrelvir‒ritonavir (Paxlovid) in hospitalized patients with COVID-19: a multicenter, retrospective, cohort study. Image Credit: Cryptographer/Shutterstock.com
In a recent study published in the Signal Transduction and Targeted Therapy, a group of researchers compared the effectiveness and safety of azvudine versus nirmatrelvir-ritonavir (Paxlovid) in hospitalized coronavirus disease 2019 (COVID-19) patients, with a focus on clinical outcomes, adverse events (AEs), and potential benefits for patients with malignant tumors.
Background
Since the outbreak of COVID-19 in…